文献速递白血病

小于3岁儿童急性髓系白血病构成分子与临床独特亚组

Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
PubMed 文献 · Br J Haematol · 2019-10-14

该研究分析日本AML99和AML-05试验中723例儿童AML患者,发现小于3岁组具有独特分子特征,KMT2A重排、CBFA2T3-GLIS2、CBFB-MYH11和NUP98-KDM5A频繁出现;CBFA2T3-GLIS2和NUP98-KDM5A预后差,且KMT2A重排和CBFB-MYH11的预后意义随年龄不同。

要点

  • 小于3岁儿童AML是分子和临床独特的亚组。
  • CBFA2T3-GLIS2和NUP98-KDM5A提示极差预后。
  • KMT2A重排和CBFB-MYH11的预后意义与年龄相关。

核心结论

  • 小于3岁儿童AML构成一个分子和临床独特的亚组。

研究设计与样本

  • 分析日本AML99和AML-05试验中723例儿童AML患者。

主要发现

  • 小于3岁组频繁出现KMT2A重排、CBFA2T3-GLIS2、CBFB-MYH11和NUP98-KDM5A。
  • CBFA2T3-GLIS2患者5年OS、EFS和CIR分别为42%、17%和83%。
  • NUP98-KDM5A患者5年OS、EFS和CIR分别为33%、17%和83%。
  • KMT2A重排小于3岁组OS、EFS和CIR显著优于3至<18岁组(P=0·023、0·011和<0·001)。
  • CBFB-MYH11小于3岁组EFS和CIR显著差于3至<18岁组(各P<0·001)。

临床怎么用

  • 对小于3岁AML患儿应进行分子分型以识别高危亚型。
  • CBFA2T3-GLIS2或NUP98-KDM5A阳性提示需关注极差预后。
  • KMT2A重排和CBFB-MYH11的预后评估需结合年龄。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although infants (age <1 year) with acute myeloid leukaemia (AML) have unique characteristics and are vulnerable to chemotherapy, children aged 1-2 years with AML may have characteristics similar to that of infants. Thus, we analysed 723 paediatric AML patients treated on the Japanese AML99 and AML-05 trials to identify characteristics of younger children. We identified patients aged <3 years (the younger group) as a distinct subgroup. KMT2A-rearrangement (KMT2A-R), CBFA2T3-GLIS2, CBFB-MYH11 and NUP98-KDM5A were frequently found in the younger group. Prognostic analyses revealed poor 5-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) in patients with CBFA2T3-GLIS2 (42%, 17% and 83%, respectively) and those with NUP98-KDM5A (33%, 17% and 83%, respectively). Additionally, we identified KMT2A-R and CBFB-MYH11 as age-specific prognostic markers. Regarding KMT2A-R, the younger group had significantly better OS, EFS and CIR than the older group (aged 3 to <18 years) (P = 0·023, 0·011 and <0·001, respectively). Conversely, concerning CBFB-MYH11, the younger group had significantly poor EFS and CIR than the older group (each P < 0·001), suggesting that certain molecular markers are linked to different prognoses according to age. Therefore, we characterized patients <3 years as a distinct subgroup of paediatric AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hara Y, Shiba N, Yamato G, et al. Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. Br J Haematol. 2019. PMID: 31612466. doi:10.1111/bjh.16203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。